Rheum for Everyone, Episode 24 (video)| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Benefits of Early Initiation of Biologic DMARDs in pJIA

Arthritis & Rheumatology  |  October 2, 2025

Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease, and polyarticular JIA (pJIA) is associated with a high risk of persistently active disease that may result in joint damage and permanent disability. Improving outcomes for children with pJIA is an important area of research.

In the previously published Start Time Optimization of biologics in Polyarticular JIA (STOP-JIA) study, researchers compared the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus treatment plans for untreated pJIA for achieving ACR clinically inactive disease off of glucocorticoids at 12 months. The treatment plans differed in the introduction of biologic disease-modifying anti-rheumatic drug (DMARD) therapy for patients as shown below:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • Step-up: Initial treatment with conventional synthetic DMARD monotherapy and the addition of a biologic DMARD at or after three months, if needed;
  • Early combination: Initial treatment with both a conventional synthetic and a biologic DMARD; and
  • Biologic first: Initial treatment with biologic DMARD monotherapy.

The results of STOP-JIA suggested that an earlier introduction of biologic DMARDs for children with pJIA may have a benefit and that the choice of initial consensus treatment plan may reduce overall disease burden.

In this follow-up study, using data from STOP-JIA, Ringold et al. sought to measure the effects of these consensus treatment plans and the timing of biologic DMARD introduction on the disease outcomes of these patients through a three-year period.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Methods

Study patients had to have participated in the STOP-JIA study and have a CARRA Registry follow-up through three years. Outcome measurements included ACR clinically inactive disease off glucocorticoids, clinical Juvenile Arthritis Disease Activity Score based on 10 joints inactive disease (cJADAS-10-ID) showing inactive disease (≤2.5), clinical remission on medication and the proportion of time in clinically inactive disease and/or cJADAS-10-ID ≤2.5.

Latent class trajectory modeling (LCTM) was applied to identify participant subgroups sharing similar disease courses over this period.

Results

In total, 297 participants were included in the study: 190 treated with the step-up consensus treatment plan, 76 treated with the early combination consensus treatment plan and 31 treated with the biologic first consensus treatment plan. At the three-year visit, clinically inactive disease was achieved by 35%, 42% and 44%, respectively (P=0.35 for step-up vs. early combination).

The early combination treatment plan was superior to the step-up plan in achieving clinical remission on medication (59.9% vs 40.6%; P=0.012), time spent in clinically inactive disease (38% vs. 30%; P=0.04) and cJADAS-10-ID scores ≤2.5 (51% vs. 41%; P=0.02). Slow, moderate and rapid improvement trajectories were identified in patients via LCTM. Biologic DMARD initiation within the first (odds ratio [OR]: 5.33) or second (OR: 2.67) month from baseline was associated with a rapid improvement trajectory.

In Sum

Overall, the three-year results of these patients from the STOP-JIA study demonstrate that early combination treatment increases the duration of time patients spend in inactive disease. The early introduction of biologic DMARDs may increase the likelihood of achieving rapid improvement and maintaining clinically inactive disease for most patients with pJIA. These improved outcomes may meaningfully reduce overall disease damage and the long-term burden of disease.

For complete details, including source material, refer to the full study.   


Excerpted and adapted from:

Ringold S, Ong MS, Tomlinson G, et al. Three-year outcomes and latent class trajectory analysis of the childhood arthritis and rheumatology research alliance polyarticular JIA consensus treatment plans study. Arthritis Rheumatol. 2025 Oct;77(10):1433–1441.

Share: 

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:biologic DMARDjuvenile idiopathic arthritis (JIA)PediatricpJIApolyarticular juvenile idiopathic arthritis (JIA)

Related Articles
    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    What Adult Rheumatologists Need to Know about Juvenile Arthritis

    May 1, 2013

    How to recognize distinctions between pediatric and adult arthritis

    Pursue Remission

    November 1, 2007

    Disease remission should be the goal for all rheumatologists treating childhood arthritis

    The Future of Pediatric Rheumatology Grounded in Evolution of Childhood Arthritis and Rheumatology Research Alliance

    December 15, 2016

    Pediatric rheumatology was formally recognized as a specialty in 1991 by the American Board of Pediatrics. Prior to this time, children with rheumatic diseases were treated by a hodgepodge of providers. In addition to providers who had training as pediatric rheumatologists, general pediatricians, adult rheumatologists, allergist-immunologists, orthopedists, pediatric infectious disease specialists and others treated children…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences